Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis

Marco A. Passini, James C. Dodge, Jie Bu, Wendy Yang, Qi Zhao, Dolan Sondhi, Neil R. Hackett, Stephen M. Kaminsky, Qinwen Mao, Lamya S. Shihabuddin, Seng H. Cheng, David E. Sleat, Gregory R. Stewart, Beverly L. Davidson, Peter Lobel, Ronald Crystal

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Classical late infantile neuronal ceroid lipofuscinosis (cLINCL) is a lysosomal storage disorder caused by mutations in CLN2, which encodes lysosomal tripeptidyl peptidase I (TPP1). Lack of TPP1 results in accumulation of autofluorescent storage material and curvilinear bodies in cells throughout the CNS, leading to progressive neurodegeneration and death typically in childhood. In this study, we injected adeno-associated virus (AAV) vectors containing the human CLN2 cDNA into the brains of CLN2-/- mice to determine therapeutic efficacy. AAV2CUhCLN2 or AAV5CUhCLN2 were stereotaxically injected into the motor cortex, thalamus, and cerebellum of both hemispheres at 6 weeks of age, and mice were then killed at 13 weeks after injection. Mice treated with AAV2CUhCLN2 and AAV5CUhCLN2 contained TPP1 activity at each injection tract that was equivalent to 0.5- and 2-fold that of CLN2+/+ control mice, respectively. Lysosome-associated membrane protein 1 immunostaining and confocal microscopy showed intracellular targeting of TPP1 to the lysosomal compartment. Compared with control animals, there was a marked reduction of autofluorescent storage in the AAV2CUhCLN2 and AAV5CUhCLN2 injected brain regions, as well as adjacent regions, including the striatum and hippocampus. Analysis by electron microscopy confirmed a significant decrease in pathological curvilinear bodies in cells. This study demonstrates that AAV-mediated TPP1 enzyme replacement corrects the hallmark cellular pathologies of cLINCL in the mouse model and raises the possibility of using AAV gene therapy to treat cLINCL patients.

Original languageEnglish
Pages (from-to)1334-1342
Number of pages9
JournalJournal of Neuroscience
Volume26
Issue number5
DOIs
Publication statusPublished - 1 Feb 2006
Externally publishedYes

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Dependovirus
Pathology
Brain
Lysosome-Associated Membrane Glycoproteins
Injections
Motor Cortex
Thalamus
Confocal Microscopy
Genetic Therapy
Cerebellum
Hippocampus
Electron Microscopy
Complementary DNA
Mutation
Enzymes

Keywords

  • AAV
  • Batten
  • LINCL
  • Lysosomal storage disease
  • Neurodegeneration
  • TPP1

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. / Passini, Marco A.; Dodge, James C.; Bu, Jie; Yang, Wendy; Zhao, Qi; Sondhi, Dolan; Hackett, Neil R.; Kaminsky, Stephen M.; Mao, Qinwen; Shihabuddin, Lamya S.; Cheng, Seng H.; Sleat, David E.; Stewart, Gregory R.; Davidson, Beverly L.; Lobel, Peter; Crystal, Ronald.

In: Journal of Neuroscience, Vol. 26, No. 5, 01.02.2006, p. 1334-1342.

Research output: Contribution to journalArticle

Passini, MA, Dodge, JC, Bu, J, Yang, W, Zhao, Q, Sondhi, D, Hackett, NR, Kaminsky, SM, Mao, Q, Shihabuddin, LS, Cheng, SH, Sleat, DE, Stewart, GR, Davidson, BL, Lobel, P & Crystal, R 2006, 'Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis', Journal of Neuroscience, vol. 26, no. 5, pp. 1334-1342. https://doi.org/10.1523/JNEUROSCI.2676-05.2006
Passini, Marco A. ; Dodge, James C. ; Bu, Jie ; Yang, Wendy ; Zhao, Qi ; Sondhi, Dolan ; Hackett, Neil R. ; Kaminsky, Stephen M. ; Mao, Qinwen ; Shihabuddin, Lamya S. ; Cheng, Seng H. ; Sleat, David E. ; Stewart, Gregory R. ; Davidson, Beverly L. ; Lobel, Peter ; Crystal, Ronald. / Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. In: Journal of Neuroscience. 2006 ; Vol. 26, No. 5. pp. 1334-1342.
@article{10ab6f28ddc64d188e1f87f63d4b466a,
title = "Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis",
abstract = "Classical late infantile neuronal ceroid lipofuscinosis (cLINCL) is a lysosomal storage disorder caused by mutations in CLN2, which encodes lysosomal tripeptidyl peptidase I (TPP1). Lack of TPP1 results in accumulation of autofluorescent storage material and curvilinear bodies in cells throughout the CNS, leading to progressive neurodegeneration and death typically in childhood. In this study, we injected adeno-associated virus (AAV) vectors containing the human CLN2 cDNA into the brains of CLN2-/- mice to determine therapeutic efficacy. AAV2CUhCLN2 or AAV5CUhCLN2 were stereotaxically injected into the motor cortex, thalamus, and cerebellum of both hemispheres at 6 weeks of age, and mice were then killed at 13 weeks after injection. Mice treated with AAV2CUhCLN2 and AAV5CUhCLN2 contained TPP1 activity at each injection tract that was equivalent to 0.5- and 2-fold that of CLN2+/+ control mice, respectively. Lysosome-associated membrane protein 1 immunostaining and confocal microscopy showed intracellular targeting of TPP1 to the lysosomal compartment. Compared with control animals, there was a marked reduction of autofluorescent storage in the AAV2CUhCLN2 and AAV5CUhCLN2 injected brain regions, as well as adjacent regions, including the striatum and hippocampus. Analysis by electron microscopy confirmed a significant decrease in pathological curvilinear bodies in cells. This study demonstrates that AAV-mediated TPP1 enzyme replacement corrects the hallmark cellular pathologies of cLINCL in the mouse model and raises the possibility of using AAV gene therapy to treat cLINCL patients.",
keywords = "AAV, Batten, LINCL, Lysosomal storage disease, Neurodegeneration, TPP1",
author = "Passini, {Marco A.} and Dodge, {James C.} and Jie Bu and Wendy Yang and Qi Zhao and Dolan Sondhi and Hackett, {Neil R.} and Kaminsky, {Stephen M.} and Qinwen Mao and Shihabuddin, {Lamya S.} and Cheng, {Seng H.} and Sleat, {David E.} and Stewart, {Gregory R.} and Davidson, {Beverly L.} and Peter Lobel and Ronald Crystal",
year = "2006",
month = "2",
day = "1",
doi = "10.1523/JNEUROSCI.2676-05.2006",
language = "English",
volume = "26",
pages = "1334--1342",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "5",

}

TY - JOUR

T1 - Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis

AU - Passini, Marco A.

AU - Dodge, James C.

AU - Bu, Jie

AU - Yang, Wendy

AU - Zhao, Qi

AU - Sondhi, Dolan

AU - Hackett, Neil R.

AU - Kaminsky, Stephen M.

AU - Mao, Qinwen

AU - Shihabuddin, Lamya S.

AU - Cheng, Seng H.

AU - Sleat, David E.

AU - Stewart, Gregory R.

AU - Davidson, Beverly L.

AU - Lobel, Peter

AU - Crystal, Ronald

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Classical late infantile neuronal ceroid lipofuscinosis (cLINCL) is a lysosomal storage disorder caused by mutations in CLN2, which encodes lysosomal tripeptidyl peptidase I (TPP1). Lack of TPP1 results in accumulation of autofluorescent storage material and curvilinear bodies in cells throughout the CNS, leading to progressive neurodegeneration and death typically in childhood. In this study, we injected adeno-associated virus (AAV) vectors containing the human CLN2 cDNA into the brains of CLN2-/- mice to determine therapeutic efficacy. AAV2CUhCLN2 or AAV5CUhCLN2 were stereotaxically injected into the motor cortex, thalamus, and cerebellum of both hemispheres at 6 weeks of age, and mice were then killed at 13 weeks after injection. Mice treated with AAV2CUhCLN2 and AAV5CUhCLN2 contained TPP1 activity at each injection tract that was equivalent to 0.5- and 2-fold that of CLN2+/+ control mice, respectively. Lysosome-associated membrane protein 1 immunostaining and confocal microscopy showed intracellular targeting of TPP1 to the lysosomal compartment. Compared with control animals, there was a marked reduction of autofluorescent storage in the AAV2CUhCLN2 and AAV5CUhCLN2 injected brain regions, as well as adjacent regions, including the striatum and hippocampus. Analysis by electron microscopy confirmed a significant decrease in pathological curvilinear bodies in cells. This study demonstrates that AAV-mediated TPP1 enzyme replacement corrects the hallmark cellular pathologies of cLINCL in the mouse model and raises the possibility of using AAV gene therapy to treat cLINCL patients.

AB - Classical late infantile neuronal ceroid lipofuscinosis (cLINCL) is a lysosomal storage disorder caused by mutations in CLN2, which encodes lysosomal tripeptidyl peptidase I (TPP1). Lack of TPP1 results in accumulation of autofluorescent storage material and curvilinear bodies in cells throughout the CNS, leading to progressive neurodegeneration and death typically in childhood. In this study, we injected adeno-associated virus (AAV) vectors containing the human CLN2 cDNA into the brains of CLN2-/- mice to determine therapeutic efficacy. AAV2CUhCLN2 or AAV5CUhCLN2 were stereotaxically injected into the motor cortex, thalamus, and cerebellum of both hemispheres at 6 weeks of age, and mice were then killed at 13 weeks after injection. Mice treated with AAV2CUhCLN2 and AAV5CUhCLN2 contained TPP1 activity at each injection tract that was equivalent to 0.5- and 2-fold that of CLN2+/+ control mice, respectively. Lysosome-associated membrane protein 1 immunostaining and confocal microscopy showed intracellular targeting of TPP1 to the lysosomal compartment. Compared with control animals, there was a marked reduction of autofluorescent storage in the AAV2CUhCLN2 and AAV5CUhCLN2 injected brain regions, as well as adjacent regions, including the striatum and hippocampus. Analysis by electron microscopy confirmed a significant decrease in pathological curvilinear bodies in cells. This study demonstrates that AAV-mediated TPP1 enzyme replacement corrects the hallmark cellular pathologies of cLINCL in the mouse model and raises the possibility of using AAV gene therapy to treat cLINCL patients.

KW - AAV

KW - Batten

KW - LINCL

KW - Lysosomal storage disease

KW - Neurodegeneration

KW - TPP1

UR - http://www.scopus.com/inward/record.url?scp=32544458154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544458154&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.2676-05.2006

DO - 10.1523/JNEUROSCI.2676-05.2006

M3 - Article

VL - 26

SP - 1334

EP - 1342

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 5

ER -